A Comparison of Different Schemes of Neoadjuvant Chemotherapy Followed by Concurrent Chemotherapy and Radiotherapy for Locally Advanced Cervical Cancer: A Retrospective Study

References

• Chen W, Zheng R, Zeng H, Zhang S. The incidence and mortality of major cancers in China, 2012. Chin J Cancer. 2016;35(1):73. doi:10.1186/s40880-016-0137-827484217
   PubMedGoogle Scholar
• Torre LA, Bray F, Siegel RL, et al. Global cancer statistics, 2012. CA Cancer J Clin. 2015;65(2):87–108.25651787
   PubMed Web of Science ®Google Scholar
• Goss PE, Strasser-Weippl K, Lee-Bychkovsky BL, et al. Challenges to effective cancer control in China, India, and Russia. Lancet Oncol. 2014;15(5):489–538.24731404
   PubMed Web of Science ®Google Scholar
• Nascimento MI, Silva GA. [Effect of waiting time for radiotherapy on five-year overall survival in women with cervical cancer, 1995–2010]. Cad Saude Publica. 2015;31(11):2437–2448. Portuguese. doi:10.1590/0102-311X0000401526840822
   PubMed Web of Science ®Google Scholar
• Thomas GM. Improved treatment for cervical cancer–concurrent chemotherapy and radiotherapy. N Engl J Med. 1999;340(15):1198–1200. doi:10.1056/NEJM19990415340150910202172
   PubMed Web of Science ®Google Scholar
• Shahid F, Farooqui Z, Khan F. Cisplatin-induced gastrointestinal toxicity: an update on possible mechanisms and on available gastroprotective strategies. Eur J Pharmacol. 2018;827:49–57. doi:10.1016/j.ejphar.2018.03.00929530589
   PubMed Web of Science ®Google Scholar
• Harmers FP, Gispen WH, Neijt JP. Neurotoxic side-effects of cisplatin. Eur J Cancer. 1991;27(3):372–376. doi:10.1016/0277-5379(91)90549-S1827334
   PubMed Web of Science ®Google Scholar
• Pabla N, Dong Z. Cisplatin nephrotoxicity: mechanisms and renoprotective strategies. Kidney Int. 2008;73(9):994–1007. doi:10.1038/sj.ki.500278618272962
   PubMed Web of Science ®Google Scholar
• Wang JQ, Wang T, Shi F, et al. A randomized controlled trial comparing clinical outcomes and toxicity of lobaplatin- versus cisplatin-based concurrent chemotherapy plus radiotherapy and high-dose-rate brachytherapy for FIGO stage II and III cervical cancer. Asian Pac J Cancer Prev. 2015;16(14):5957–5961. doi:10.7314/APJCP.2015.16.14.595726320479
   PubMedGoogle Scholar
• McKeage MJ. Lobaplatin: a new antitumour platinum drug. Expert Opin Investig Drugs. 2001;10(1):119–128. doi:10.1517/13543784.10.1.119
   PubMed Web of Science ®Google Scholar
• Li F, Wang B, He M, et al. Pilot study of docetaxel combined with lobaplatin or gemcitabine for recurrent and metastatic breast cancer. Medicine. 2019;98(52):e18513. doi:10.1097/MD.000000000001851331876741
   PubMed Web of Science ®Google Scholar
• Chen J, Liu B, Zhang F, Cui W, Zhang P. Pharmacokinetics and safety of lobaplatin plus etoposide in Chinese men older than 65 years with extensive-stage small cell lung cancer: a phase II clinical trial. Cancer Chemother Pharmacol. 2019;84(1):73–81. doi:10.1007/s00280-019-03828-z31041509
   PubMed Web of Science ®Google Scholar
• Pecorelli S. Revised FIGO staging for carcinoma of the vulva, cervix, and endometrium. Int J Gynaecol Obstet. 2009;105(2):103–104. doi:10.1016/j.ijgo.2009.02.01219367689
   PubMed Web of Science ®Google Scholar
• Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45(2):228–247. doi:10.1016/j.ejca.2008.10.02619097774
   PubMed Web of Science ®Google Scholar
• National Cancer Institute. Common terminology criteria for adverse events (CTCAE) v4.0; 2009. Available from: http://evs.nci.nih.gov/ftp1/CTCAE/About.html. Accessed June 4, 2021.
   Google Scholar
• Cox JD, Stetz J, Pajak TF. Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC). Int J Radiat Oncol Biol Phys. 1995;31(5):1341–1346. doi:10.1016/0360-3016(95)00060-C7713792
   PubMed Web of Science ®Google Scholar
• IBM SPSS Statistics for Windows, Version 24.0. Armonk, NY: IBM Corp; 2016. Available from: https://www-01.ibm.com/support/docview.wss?uid=swg21476197. Accessed June 4, 2021.
   Google Scholar
• Neoadjuvant Chemotherapy for Locally Advanced Cervical Cancer Meta-analysis Collaboration. Neoadjuvant chemotherapy for locally advanced cervical cancer: a systematic review and meta-analysis of individual patient data from 21 randomised trials. Eur J Cancer. 2003;39(17):2470–2486.14602133
   PubMed Web of Science ®Google Scholar
• de Azevedo C, Thuler LCS, de Mello MJG, et al. Phase II trial of neoadjuvant chemotherapy followed by chemoradiation in locally advanced cervical cancer. Gynecol Oncol. 2017;146(3):560–565. doi:10.1016/j.ygyno.2017.07.00628709705
   PubMed Web of Science ®Google Scholar
• Narayan S, Sharma N, Kapoor A, et al. Pros and cons of adding of neoadjuvant chemotherapy to standard concurrent chemoradiotherapy in cervical cancer: a regional cancer center experience. J Obstet Gynaecol India. 2016;66(5):385–390. doi:10.1007/s13224-015-0698-527486286
   PubMedGoogle Scholar
• Harsh KK, Kapoor A, Paramanandhan M, et al. Induction chemotherapy followed by concurrent chemoradiation in the management of different stages of cervical carcinoma: 5-year retrospective study. J Obstet Gynaecol India. 2016;66(5):372–378. doi:10.1007/s13224-015-0699-427486284
   PubMedGoogle Scholar
• Buda A, Fossati R, Colombo N, et al. Randomized trial of neoadjuvant chemotherapy comparing paclitaxel, ifosfamide, and cisplatin with ifosfamide and cisplatin followed by radical surgery in patients with locally advanced squamous cell cervical carcinoma: the SNAP01 (Studio Neo-Adjuvante Portio) Italian Collaborative Study. J Clin Oncol. 2005;23(18):4137–4145.15961761
   PubMed Web of Science ®Google Scholar
• Yang Z, Chen D, Zhang J, et al. The efficacy and safety of neoadjuvant chemotherapy in the treatment of locally advanced cervical cancer: a randomized multicenter study. Gynecol Oncol. 2016;141(2):231–239. doi:10.1016/j.ygyno.2015.06.02726115978
   PubMed Web of Science ®Google Scholar
• Benedetti Panici P, Bellati F, Pastore M, et al. An update in neoadjuvant chemotherapy in cervical cancer. Gynecol Oncol. 2007;107(1 Suppl 1):S20–S22. doi:10.1016/j.ygyno.2007.07.04117727927
   PubMed Web of Science ®Google Scholar
• Moore DH, Blessing JA, McQuellon RP, et al. Phase III study of cisplatin with or without paclitaxel in stage IVB, recurrent, or persistent squamous cell carcinoma of the cervix: a gynecologic oncology group study. J Clin Oncol. 2004;22(15):3113–3119. doi:10.1200/JCO.2004.04.17015284262
   PubMed Web of Science ®Google Scholar
• Monk BJ, Sill MW, McMeekin DS, et al. Phase III trial of four cisplatin-containing doublet combinations in stage IVB, recurrent, or persistent cervical carcinoma: a Gynecologic Oncology Group study. J Clin Oncol. 2009;27(28):4649–4655. doi:10.1200/JCO.2009.21.890919720909
   PubMed Web of Science ®Google Scholar
• Whitney CW, Sause W, Bundy BN, et al. Randomized comparison of fluorouracil plus cisplatin versus hydroxyurea as an adjunct to radiation therapy in stage IIB-IVA carcinoma of the cervix with negative para-aortic lymph nodes: a Gynecologic Oncology Group and Southwest Oncology Group study. J Clin Oncol. 1999;17(5):1339–1348. doi:10.1200/JCO.1999.17.5.133910334517
   PubMed Web of Science ®Google Scholar
• Singh RB, Chander S, Mohanti BK, et al. Neoadjuvant chemotherapy with weekly paclitaxel and carboplatin followed by chemoradiation in locally advanced cervical carcinoma: a pilot study. Gynecol Oncol. 2013;129(1):124–128. doi:10.1016/j.ygyno.2013.01.01123353129
   PubMed Web of Science ®Google Scholar
• Kirwan JM, Symonds P, Green JA, et al. A systematic review of acute and late toxicity of concomitant chemoradiation for cervical cancer. Radiother Oncol. 2003;68(3):217–226. doi:10.1016/S0167-8140(03)00197-X13129628
   PubMed Web of Science ®Google Scholar
• Dueñas-González A, Zarbá JJ, Patel F, et al. Phase III, open-label, randomized study comparing concurrent gemcitabine plus cisplatin and radiation followed by adjuvant gemcitabine and cisplatin versus concurrent cisplatin and radiation in patients with stage IIB to IVA carcinoma of the cervix. J Clin Oncol. 2011;29(13):1678–1685. doi:10.1200/JCO.2009.25.966321444871
   PubMed Web of Science ®Google Scholar
• Kuroda Y, Murakami N, Morota M, et al. Impact of concurrent chemotherapy on definitive radiotherapy for women with FIGO IIIb cervical cancer. J Radiat Res. 2012;53(4):588–593. doi:10.1093/jrr/rrs01022843624
   PubMed Web of Science ®Google Scholar
• Gupta S, Maheshwari A, Parab P, et al. Neoadjuvant chemotherapy followed by radical surgery versus concomitant chemotherapy and radiotherapy in patients with stage IB2, IIA, or IIB squamous cervical cancer: a randomized controlled trial. J Clin Oncol. 2018;36(16):1548–1555. doi:10.1200/JCO.2017.75.998529432076
   PubMed Web of Science ®Google Scholar
• Ginsburg O, Bray F, Coleman MP, et al. The global burden of women’s cancers: a grand challenge in global health. Lancet. 2017;389(10071):847–860. doi:10.1016/S0140-6736(16)31392-727814965
   PubMed Web of Science ®Google Scholar
• Park DC, Kim JH, Lew YO, Kim DH, Namkoong SE. Phase II trial of neoadjuvant paclitaxel and cisplatin in uterine cervical cancer. Gynecol Oncol. 2004;92(1):59–63. doi:10.1016/j.ygyno.2003.09.01514751139
   PubMed Web of Science ®Google Scholar
• Dueñas-Gonzalez A, López-Graniel C, González-Enciso A, et al. A phase II study of multimodality treatment for locally advanced cervical cancer: neoadjuvant carboplatin and paclitaxel followed by radical hysterectomy and adjuvant cisplatin chemoradiation. Ann Oncol. 2014;50(4):877–887.
   Google Scholar